Navigation Links
Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Date:12/19/2007

ate the safety and tolerability of treatment with Amigal. The secondary objective was to evaluate certain pharmacodynamic measures of treatment, including effects on a-GAL (the target enzyme deficient in Fabry patients) and levels of GL-3 (the substrate that builds up in the cells of patients) in cells and tissues affected by the disease. An additional objective was the preliminary assessment of cardiac and renal function.

The four open-label, multi-national Phase 2 trials of Amigal enrolled 18 men and 9 women with Fabry disease between the ages of 17 and 65. The four studies examined various dose levels and frequencies of Amigal administration and had 12 or 24 week primary treatment arms with an optional treatment extension.

Twenty-six patients completed the primary treatment arms and all entered the optional treatment extension. The 26 patients had 21 different missense genetic mutations that cause Fabry disease. The mutations represented the full spectrum of Fabry patients, including those with both early-onset and late- onset forms of the disease. Twenty-three patients are currently being treated with Amigal under the treatment extension, including 8 who have been treated for more than a year and 4 who have been treated for almost 2 years.

"The positive results of these first trials of a pharmacological chaperone in Fabry disease are impressive," said Raphael Schiffmann, M.D., Lead Investigator at the Metabolic Neurology Branch of the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health, and a principal investigator in one of the Amigal clinical trials. "I believe this technology has the potential to be an important new treatment option for many Fabry disease patients."

The key findings in the Phase 2 studies were:

* Amigal was generally safe and well-tolerated at all doses evaluated. No

drug-related serious adverse events were reported during the primary


'/>"/>
SOURCE Amicus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... RURO Inc. is pleased to ... versatile refinement to the smart management solution. , ... advanced methodical management for transgenic animal colonies, genotyping ... network-based platform provides user access with a plethora ... to emphasize streamlined tasks, such as animal relocation ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 ... Barbara A. Myers, CAE, to the newly created ... her new role, Myers will be responsible for ... and production strategies, advancing the Society’s Member-led and ... and continuing to refine organizational, membership and product ...
(Date:5/16/2013)... Kitware , a leading provider ... Phase II SBIR funding from the U.S. Department ... open-source, high performance computing (HPC) simulation and computation ... to select only the toolkits and applications needed ... analysis tasks. , Manufacturers increasingly rely on ...
(Date:5/16/2013)... 2013 On average, developing a new ... billion dollars. Despite this investment, less than 10% of ... is your clinical trial design optimally structured to balance ... , Dr. Frederic Sax, Global Head of the Center ... of data, information and technology in upfront clinical trial ...
Breaking Biology Technology:RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2
... Food Safety Authority (EFSA) concludes no safety concerns for ... response to Nutrition 21,s Application to market Chromax(R) chromium ... PURCHASE, N.Y., June 30 Nutrition 21, Inc. (Nasdaq: ... nutritional supplements under the Iceland Health(R) and Diabetes Essentials ...
... SEATTLE, June 30 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... 3000(R), Russell 2000(R) and Russell Global(R) Indexes posted by Russell Investments ... Russell Investments reconstitutes its family of U.S. and global equity indexes ... of Russell,s U.S. indexes captures the 4,000 largest U.S. stocks as ...
... , FRANKLIN LAKES, N.J., June 29 BD (Becton, ... it will conduct a live webcast of its third fiscal quarter ... a.m. (EDT). BD will issue a press release detailing the ... the conference call, along with related slides, will be accessible through ...
Cached Biology Technology:EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 2EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 3EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 4Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes 2Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes 3
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) Program ... Endocrine Society (ENDO) 95th Annual Meeting in San ... are meant to promote the entry of students, ... mainstream of the basic science community and to ... ENDO 2013 Annual Meeting. , Awards are given ...
(Date:5/16/2013)... decades, scientists have used ancient shorelines to predict the stability ... of a high shoreline from three million years ago, for ... were thought to be evidence of a high sea ... assumption has led many scientists to think that if the ... may do just the same in our modern, progressively warming ...
(Date:5/16/2013)... The endothelium, the cellular layer lining the body,s ... few hundred nanometers in thickness, this super-tenuous structure ... tissue compression to create a unique and highly ... partition tissues from the body,s circulatory system. , ... barrier must be physically breached to enable ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... organisms such as worms and flies can now be ... by engineers at the Georgia Institute of Technology. ... phenotype of and sort small animals, such as the ... studies. "Classical genetic approaches require altering genetic information ...
... over a million and a half acres of Appalachia have ... slurry left behind, and communities devastated. Not exactly a promising ... maybe it is. For his startling and bold proposal ... World: The Challenge of Appalachia, John Todd, a research professor ...
... the heart,s earliest origins. Now, they have pinpointed a new, ... cardiomyocytes, or heart muscle cells. These stem cells, located in ... of being able to regenerate injured heart tissue. ... on June 22, comes on the heels of parallel cardiac ...
Cached Biology News:Automated microfluidic device reduces time to screen small organisms for genetic studies 2Automated microfluidic device reduces time to screen small organisms for genetic studies 3Buckminster Fuller takes on big coal 2Buckminster Fuller takes on big coal 3New source of heart stem cells discovered 2New source of heart stem cells discovered 3New source of heart stem cells discovered 4
Full-length cDNA 5-PRIME end of clone CS0DE013YM09 of Placenta of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86TS7] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... atoms at the 9, 10, 12, and 13 ... internal standard for the quantification of 9(S)-HODE by ... the lipoxygenation of linoleic acid in both plants ... plaques, as an esterified component of membrane phospholipids ...
... 9(S)-HODE-d4 contains 4 deuterium atoms at the 9, ... for use as an internal standard for the ... 9(S)-HODE is produced by the lipoxygenation of linoleic ... been detected in atherosclerotic plaques, as an esterified ...
Biology Products: